1,250 polypill patients/ month could potentially grow revenues to $1M a year according to our sales model.  We project to retain a high % of customers each month since we are one of the only low-price sources for CVD polypills in the USA.

~60 million people. 24% of adults in the U.S. take more than 3 pills per day. There are 250m+ adults in the US. Yes, that's a big number who OneFul Health's personalized polypill could hopefully serve.

In the short time since we launched the raise, we announced 2 major partnerships which have the potential to put us in front of thousands of additional providers and patients who can take a < 5 min survey to see if they qualify for the personalized polypill. That's on top of our existing customer base and health provider network. We already have a list of other potential partners who reached out to us because they saw our raise. 

Thank you to everyone who has invested so far. 

To grow OneFul Health together, here's all we ask you to do. 

Share our simple survey to see who in your network may qualify for the personalized polypill.

We already have applications coming in.

Wishing you wealth and health.

Dr. Andrew Schwab - VC and Cardiovascular Patient Explains Why He Invested

Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups.   He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.

Why he invests in OneFul Health - 3 minutes -  Youtube - Why Dr. Schwab Invested in OneFul https://youtu.be/Dy3vaVhnUHw&nbsp; 

To view the full 20-minute interview describing his journey from an investor to being a cardiovascular patient who understands first-hand the benefits of OneFul's personalized polypill, visit OneFul's website at www.oneful.health .

This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.

Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups.   He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.

Why he invests in OneFul Health - 3 minutes -  Youtube - https://youtu.be/Dy3vaVhnUHw 

To view the full 20 minute interview describing his journey from investor to being a cardiovascular patient who understands first  hand the benefits of OneFul's personalized polypill, visit OneFul's website at www.oneful.health  

Every 34 seconds in the United States, an adult dies from preventable cardiovascular disease (CVD).1 These are mothers, fathers, sisters, brothers, and friends—all gone because of a disease that is largely preventable.

• 4.1 Million not taking aspirin or blood thinners as recommended
• 67.8 Million with uncontrolled BP (≥ 130/80 mm Hg)
• 37.5 Million not taking statins as recommended

The need is great, and the market size is enormous. The North America cardiovascular drug market size is around US $ 31.85 Bn in 2022 and is projected to reach US $ 43.40 Bn in 20302.

Twenty years ago next month, a paper entitled “PolyPill - “A strategy to reduce cardiovascular disease by more than 80%” Wald, Law ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC162259/). Since then over 30,000 patients in other countries have used a version of the polypill, which has shown to reduce the risk of major cardiac events by 50% on average. So this is a way to help control this terrible disease – the polypill.

Until now, no polypill product or service exists in the USA, and no personalized, patient-specific product has been offered anywhere in the world. 

Oneful is the First Pharmacy Online Platform to enable low-cost, personalized and precision cardiovascular prevention using its robotic “Single-pill combination” technology.    Without this technology, accredited pharmacy infrastructure, and physician partnerships, no other company can provide such a product at an affordable price, as low as $1.00 a day. Based on our extensive industry technical knowledge and research and 20 years of operating experience in the compounding pharmacy industry, our management team believes that our patented technology and regulatory plan give us substantial competitive advantages to manufacture precision treatments that reduce cardiac events profitably at affordable costs to consumers.

Invest now, as this is going to happen. Will OneFul own the whole personalized polypill market forever? Unlikely once Big Pharma and Insurance start to see the savings of lives and budgets due to the reduction in this costly disease. Get onboard before the big guys get out their checkbooks!

1 https://millionhearts.hhs.gov/about-million-hearts/index.html

2 US Cardiovascular Drugs Market Analysis Report [2022-30] I Insights10 (https://www.insights10.com/report/us-cardiovascular-drugs-market-analysis/#:~:text=The%20North%20America%20Cardiovascular%20Drug%20Market%20size%20is,a%20CAGR%20of%205.4%25%20during%20the%20forecast%20period.)

Making Heart Medicines Work Better with Genomics-  Geneticure and OneFul Health Partner for Precision Polypills 

Geneticure Inc (geneticure.com) and OneFul Health Inc (oneful.health) are teaming up to combine genomic-based formulation and personalized medicine to create precision treatments that work better for cardiovascular patients. Their joint mission is to help prevent heart attacks and strokes, focusing on better high-blood pressure treatments. 

Hypertension or high blood pressure is a significant risk for several medical conditions, including coronary artery disease, stroke, heart failure, atrial fibrillation, vision loss, chronic kidney disease, and dementia. According to the CDC 2020 data, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

Geneticure is a team of hypertension expert scientists and doctors based in Rochester, Minnesota, home of the Mayo Clinic —also an investor in Geneticure. For ten years, Geneticure's scientists have put science and innovation to work, taking personalized medicine to the next level, unmatched in the world of pharmacogenomics. With their home-collected test using the DNA on a cheek swab, Geneticure recommends which hypertension medication(s) may give the biggest drop in blood pressure. This information, supplied to specialist cardiologists, will aid OneFul Health in formulating the most effective precision polypill for each individual. 

OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule or gel packet. Hypertension often can only be controlled by using multiple medication classes at dosages that vary significantly among individuals. OneFul will send HIPAA-secured data generated by Geneticure to partner cardiologists or the person's doctor. Geneticure's custom report enables OneFul and its physician partners to formulate a precision polypill for hypertension optimized to each person's genetics. The optimized multi-drug prescription to control hypertension and other heart risks is transmitted to OneFul's accredited pharmaceutical facility where it is made on demand using it's patented robotic process to ensure quality. This personalized polypill is then made on demand using only certified lab-tested purity and cardiovascular drugs proven safe in trials of over 30,000 patients.

Both companies are committed to quality care and direct-to-patient services to create custom treatments that improve the quality of life and ease patient adherence. Geneticure agrees to work with OneFul Health to develop medical protocols for precision polypills and to study the benefits to patients of their joint development. The Geneticure and the OneFul Health teams are excited by the potential to improve cardiovascular treatment, bringing precision cardiology to market.  

Based on our online polypill qualification survey, OneFul Health is adding 10 new candidates daily to its waiting list by for a personalized cardiovascular polypill combining 3 to 7 pills into one convenient, made-to-order capsule.

Our five-minute online HIPAA secure survey gathers the information that allows us to screen the best candidates for this personalized combination treatment. Working with HeartBeat Health's cardiologist or doctor, we can make the optimal formulation to reduce cardiovascular risks.  Our combination of approved medications has been shown in clinical trials to reduce the annual risk of heart attack and stroke by up to 50%.  

Will this innovation help you or your loved ones have a better chance at a healthy longer life?

Take the survey here and let’s see how we can help.

https://onefulhealth.surveysparrow.com/s/polypill-survey1/tt-3FXWQCvbrtuqmHk63HzfXm 

Cardiovascular health is a medical domain where AI may be a fantastic tool for new drug and treatment discovery, but it may not be a panacea. Dr. Eric Topol reported on a continuous blood pressure monitoring bracelet about advances in non-compression-based wearable tech (https://erictopol.substack.com/p/a-continuous-blood-pressure-monitoring). A new study ( https://www.medscape.com/viewarticle/990739?src=soc_lk_share) reported about substantial variation in the blood pressure response to various antihypertensive medications between individuals, raising the possibility of need for personalized therapy. At OneFul Health, we are working with teams that will make AI will be a fantastic tool to predict the starting formulation for a precision polypill at the individual level. AIs will best integrate an individual's digital health profile, including pharmacogenomics, metabolic factors, and epigenetics. So, AIs will likely soon provide the most competent predictive personalized treatment recommendations. However, even such data-intensive AI-based treatment prescriptions cannot readily include the complete real-world individual picture, distorted by the hyper-complexity of current drug interactions, their microbiome health, diet and exercise. That is where closed-loop continuous monitoring and communication from daily wearables like an Apple Watch or Fitbit come into play. Such devices linked to AI, may bring about a whole new model for several aspects of cardiovascular preventative care. Using tech tools like Zio (https://www.irhythmtech.com/patients/how-it-works), as an in-home continuous monitor for electrophysiological factors by HeartBeat Health, (heartbeatheatlh.com),  and other cardiologists is already accepted. Dynamic control in all complex systems has historically been optimized only by using near real-time feedback, as taught by famed MIT mathematician Norbert Wiener (https://en.wikipedia.org/wiki/Norbert_Wiener). With broadband infrastructure and the pervasive adoption of personal wearables, the time is here to embrace the use of closed-loop continuous monitoring and communication from daily wearables, as it has the potential to revolutionize several aspects of cardiovascular preventative care. At OneFul Health, we believe that predictive AI will unlikely be successful at preventing cardiovascular events without closing the loop at the individual level. A modernized protocol that augments AI recommendations with closed-loop continuous monitoring and communication from daily wearables to optimize precision polypills for personalized treatments can be a cardiovascular care game-changer. We believe this closed-loop approach will be better than any AI, for complex diseases such as mental health, where wearable devices or simple smartphone feedback can help formulate optimal therapies for individuals.

An important article in USA Today is "Why are so many Black patients dying from heart failure?" .Black patients are more likely to die of heart failure. Why? (https://www.usatoday.com/story/opinion/2023/04/10/black-patients-die-heart-failure-more-health-care-inequities/11552017002/ ).  Dr. Munoz et al at Vanderbilt University Medical Center researched an approach to a partial solution and was published in the New England Journal of Medicine in 2019. (https://www.nejm.org/doi/full/10.1056/NEJMoa1815359) |. Until recently, the polypill concept rarely included all the right drugs or therapeutic doses to treat heart failure. Our work at www.oneful.health removes that limitation allowing individualized physician-prescribed combinations in a single personalized polypill that can include heart-failure medications while keeping out-of-pocket costs typically to $1/day. Remote access issues are addressed by cooperating with leading telemedicine specialist cardiologist networks, like partners at HeartBeat Health. This new approach to personalized cardiovascular polypills prescribed online and accurately made with robotic on-demand manufacturing can potentially reduce cardiovascular risks in populations not adequately covered by insurance in remote, underserved locations. Personalized polypills reduce most common cardiovascular risks and can be prescribed and delivered directly to at-risk individuals. The post-COVID era will show how such technologies as OneFul.Health has developed can be employed to address health equity. 

Personalized Medicine Meets Virtual Care Cardiology:

Heartbeat Health and OneFul Health Partner to Prevent Heart Attacks and Strokes

March 28, 2023,  New York, NY and Research Triangle Park, NC 

Heartbeat Health and OneFul Health have teamed up to bring telemedicine and personalized medicine together, providing individuals with unique treatments to help prevent heart attacks and strokes, delivered right to their homes.

Heartbeat Health is founded by Dr. Jeffrey Wessler, a cardiologist-entrepreneur who leveraged his academic expertise to create a new standard for Virtual-First Cardiology care. Heartbeat is revolutionizing cardiovascular care, one virtual intervention at a time, and is the perfect partner for OneFul. This combination of innovative healthcare technology companies will deliver direct-to-patient personalized cardiovascular disease prevention and management services.

OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule.  Using only certified lab-tested purity and proven safe cardiovascular drugs trialed in over 30,000 patients, OneFul formulates personalized pharmaceutical treatments with its patented pharm tech automation platform, invented by founder and robotics expert Edison Hudson.

OneFul will send HIPAA-controlled data about pre-qualified polypill patients to Heartbeat, whose cardiologists will qualify patients for personalized polypill treatments, creating custom prescriptions that match each patient's medical needs. Their multi-drug prescription is then transmitted to OneFul's accredited pharmaceutical facility, managed by 20+ year veteran Pharmacist Danny Barnes. His PharmD team reviews and accurately fills each script using high-accuracy technology.

Both companies are committed to quality care and direct-to-patient services, making specialized cardiology consultations accessible and fast to schedule, along with custom treatments that make life and medication adherence easier for patients. Plans include integrating pharmacogenomics and in-home biomarker testing to improve treatment effectiveness further and reduce adverse effects. HeartBeat agrees to work with OneFul Health to create medical protocols for precision polypills that can be applied to any patient by their national network of cardiologists.

Heartbeat Health and OneFul Health teams are excited by the potential to improve cardiovascular treatment, providing the best in telemedicine and personalized medicine to prevent heart attacks and strokes and ushering in a new era of personalized cardiovascular care.

onefulhealth.com/ heartbeathealth.com 

Watch Edison Hudson, CEO/Founder speak about Oneful Personalized, Precision, Preventative Polypill -  https://youtu.be/FEbxfbvTrRM 

Imagine having the power to change lives and prevent heart disease in millions of Americans. With our Cardiovascular Precision Preventative Polypill, or CVD-P3, we have the opportunity to make a significant impact in the world of medicine. Some of you may have had questions about our product and its potential impact. Rest assured, the market for our product is enormous. Over 14 million Americans have diagnosed coronary artery disease, and a large portion of these individuals could benefit from using CVD-P3.

Our product is specially designed for patients who take multiple post-operation drugs to reduce risk. This includes patients who have received stents and coronary artery bypass graft surgery, which amounts to 2 million and 340,000 people per year, respectively. And it doesn't stop there. CVD-P3 can also be formulated to address specific genomic risk factors, common in some families - 27.8 million people over 20 years of age.

With the impact of COVID-19, the risks for heart disease have only increased. Dr. Eric Topol, in his recent article on Substack, mentions the 1.7-fold risk of heart attack and 1.6-fold increased risk of stroke. This means that there is an even greater need for preventative measures like CVD-P3.

But let's talk about the numbers. Our model predicts that we can achieve revenue of $100M by serving just 1.5 million customers per year - a feasible number with 25 of our robotic compounders. And that's just the beginning. Imagine the potential impact of our future pipeline, which includes addressing diabetes, metabolic diseases, and mental health.

So, let's take control of the future of medicine and make a real difference in the lives of millions. Join us in our mission to prevent heart disease and pave the way for a healthier world. Listen to Edison Hudson, our CEO explain more about our revolutionary CVD-P3 personalized product. 

Data Sources: https://www.nih.gov/news-events/nih-research-matters/bypass-surgery-shows-advantage ;  https://idataresearch.com/stents-implanted-per-year-in-the-u-s/#:~:text=iData%20Research%2C%20a%20leading%20international%20market%20research%20and,stents%20implanted%20per%20year%20in%20the%20United%20States. ; https://idataresearch.com/new-study-shows-approximately-340000-cabg-procedures-per-year-in-the-united-states/#:~:text=According%20to%20a%20new%20cardiac%20surgery%20study%20by,grafted%20onto%20the%20heart%20to%20bypass%20blocked%20arteries. ; https://www.ahajournals.org/doi/10.1161/JAHA.119.012364#:~:text=Using%20a%20representative%20sample%20of%20the%20US%20population%2C,cardiovascular%20disease%20can%20be%20identified%20using%20family%20history. ; https://erictopol.substack.com/p/heart-attacks-and-strokes-late-after 

StartEngine Forward Looking Statements:

The statements in the article are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this update are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.